ArticleDrug delivery and translational research2017
Skin targeting of resveratrol utilizing solid lipid nanoparticle-engrossed gel for chemically induced irritant contact dermatitis.
Article in Drug delivery and translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- The bioactivities of resveratrol and its naturally occurring derivatives on skin.Journal of food and drug analysis · 2021Pooled it
- Design and Factorial Optimization of Curcumin and Resveratrol Co-Loaded Lipid Nanocarriers for Topical Delivery.Pharmaceutics · 2026Article
- Progress and Prospects of Transdermal Treatment of Allergic Skin Diseases with Natural Drugs based on Nanotechnology.AAPS PharmSciTech · 2025Review
- Lipid-Based Drug Delivery Systems: Concepts and Recent Advances in Transdermal Applications.Nanomaterials (Basel, Switzerland) · 2025Review
- Psoriasis: Unraveling Disease Mechanisms and Advancing Pharmacological and Nanotechnological Treatments.Journal of inflammation research · 2025Review
- Nose-to-Brain Targeting of Resveratrol Nanoformulations.Current vascular pharmacology · 2025Review
- Effects of Resveratrol on Nonmelanoma Skin Cancer (NMSC): A Comprehensive Review.Food science & nutrition · 2024Review
- The development of a solid lipid nanoparticle (SLN)-based lacticin 3147 hydrogel for the treatment of wound infections.Drug delivery and translational research · 2023Article
- Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis.Pharmaceutics · 2023Review
- Formulation of Aucklandiae Radix Extract-Loaded Nanoemulsions and Its Characterization and Evaluations In Vitro and In Vivo.Applied biochemistry and biotechnology · 2023Article
- Hyaluronic Acid Hydrogel Containing Resveratrol-Loaded Chitosan Nanoparticles as an Adjuvant in Atopic Dermatitis Treatment.Journal of functional biomaterials · 2023Article
- Design and development of topical liposomal formulations in a regulatory perspective.Drug delivery and translational research · 2022Article
- Lipid Nanoparticulate Drug Delivery Systems: Recent Advances in the Treatment of Skin Disorders.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Topical Gel of Vitamin A Solid Lipid Nanoparticles: A Hopeful Promise as a Dermal Delivery System.Advanced pharmaceutical bulletin · 2021Article
- Omega-3- and Resveratrol-Loaded Lipid Nanosystems for Potential Use as Topical Formulations in Autoimmune, Inflammatory, and Cancerous Skin Diseases.Pharmaceutics · 2021Article
- Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics.International journal of molecular sciences · 2021Review
- The Use of Micro- and Nanocarriers for Resveratrol Delivery into and across the Skin in Different Skin Diseases-A Literature Review.Pharmaceutics · 2021Review
- Strategies to Improve Resveratrol Systemic and Topical Bioavailability: An Update.Antioxidants (Basel, Switzerland) · 2019Review
- Resveratrol as a Multifunctional Topical Hypopigmenting Agent.International journal of molecular sciences · 2019Review
- Resveratrol solid lipid nanoparticles to trigger credible inhibition of doxorubicin cardiotoxicity.International journal of nanomedicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritant contact dermatitis (ICD) is a chronic and relapsing skin disease with severe eczematous lesions. Despite its growing prevalence, therapeutic treatments remain limited. Long-term topical corticosteroid treatment can induce skin atrophy, hypopigmentation, and increase in transepidermal water loss. An innovative dermal treatment is essential to reduce the side effects of corticosteroids. Topical resveratrol (RES), although effective for ICD, is a challenging molecule due to low solubility and poor bioavailability. The objective of this work was to build RES-loaded solid lipid nanoparticles (RES-SLNs) with skin targeting. For this purpose, RES-SLNs were prepared using the probe ultrasonication method utilizing Precirol ATO 5 and Tween 20. The RES-SLNs were evaluated for particle size, entrapment efficiency (EE), and transmission electron microscopy (TEM) studies. Further, RES-SLNs were incorporated into Carbopol gel and investigated for ex vivo skin permeation, deposition study on human cadaver skin, and finally skin irritation study on New Zealand White rabbits. It was further assessed for possible beneficial effects on ICD using BALB/c mice. RES-SLN showed mean size below 100 nm and 68-89% EE. TEM studies confirmed spherical particles in the nanometer range. An ex vivo study of RES-SLN-loaded gel exhibited controlled drug release up to 24 h; similarly, in vitro drug deposition studies showed potential of skin targeting with no skin irritation. RES-SLN gel confirmed competent suppression of ear swelling and reduction in skin water content in the BALB/c mouse model of ICD when compared to marketed gel. Thus, the formulated RES-SLN gel would be a safe and effective alternative to conventional vehicles for treatment of ICD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.